Moonwalk Biosciences
Moonwalk Biosciences, Inc.
By deeply profiling and targeting the epigenetic code, Moonwalk aims to reprogram cells to their healthy state, fundamentally enabling a new approach to how therapies are discovered and developed.
moonwalk.bio · South San Francisco, CA
Funding event
The round itself, as filedInferred stageSeries B
Sold of offered$60.0M of $70.2M
Filed2026-09-14
Days since filing19
- Exemption claimed
- Rule 506(b)
- First-ever Form D
- No
- Date of first sale
- 2026-08-26
Investors
No investors named: Form D does not list them
Officers on the filing
Names and roles as filed; addresses are never stored- Alexander AravanisExecutive Officer · Director
- Arash JamshidiExecutive Officer · Director
- Chris DimitropoulosDirector
- Paul BurtonDirector
- Justin ValleyExecutive Officer
- Elaine CheungExecutive Officer
- Stephen DjedjosExecutive Officer
- John LilesExecutive Officer
Health flags
Three flags, each with the raw inputs behind it · as of 2026-10-03UndersubscribedNot flagged85.4% sold1.2 months since first sale
Prior raiseNot flaggedPrior raise not known—
AmendedNot flaggedNo amendmentNo D/A on file
Open roles
On the employer's own careers page · checked 2026-09-213
Pre-posting windowNot enough dataShown once this sector and stage have 20 observed lags from filing to first posting.
- (Senior) Research Associate, In Vivo PharmacologySEP 21Moonwalk Biosciences · Full-time · open 13 days
- Scientist/Engineer, Machine Learning / BioinformaticsSEP 21Moonwalk Biosciences · Full-time · open 13 days
- General InterestSEP 21Moonwalk Biosciences · Full-time · open 13 days
Also raised in Health & bio
Same sector, 28 days to 2026-10-04Altay TherapeuticsSeries A · $15.7M of $45.1M · San Carlos, CAQuietCarebilitySeries A · $8.8M of $8.8M · Richardson, TXQuiet
75 rounds in Health & bio in the 28 days to 2026-10-02, against 71 in the 28 days before.